Michael J. Overman

32.0k citations
454 papers · 16.9k · 7 hit papers · h-index 59

Impact in

  • Oncology top 0.05%
    • Colorectal Cancer Treatments and Studies
    • Cancer Immunotherapy and Biomarkers
    • Pancreatic and Hepatic Oncology Research
  • Hepatology top 0.2%
    • Hepatocellular Carcinoma Treatment and Prognosis

Papers in

    • Colorectal Cancer Treatments and Studies 154
    • Cancer Immunotherapy and Biomarkers 66
    • Pancreatic and Hepatic Oncology Research 47
    • Genetic factors in colorectal cancer 99

Michael J. Overman

431 papers receiving 16.7k citations

Michael J. Overman's Hit Papers

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 2022 · 167 citations
1670+6+12Years since publication50010001.5k2.0k

Peers

Michael J. Overman
Comparison fields: 5 of 144
  • Oncology 8.9k
  • Hepatology 1.8k
  • Pathology and Forensic Medicine 3.1k
  • Gastroenterology 918
  • Cancer Research 2.4k
Replace Andrés Cervantes with:
Andrés Cervantes Spain
Valérie Boige France
Filippo de Braud Italy
Stefano Cascinu Italy
Ian Chau United Kingdom
Olivier Bouché France
Ho Yeong Lim South Korea
Marc Ychou France
Niall C. Tebbutt Australia
Jordan Berlin United States
Michael J. Overman relative to Andrés Cervantes Spain Andrés Cervantes's profile →
Citations per field
00.5×1.5×
Andrés Cervantes · 1×
Citations per year

Countries citing papers authored by Michael J. Overman

Since Specialization
Citations

This map shows the geographic impact of Michael J. Overman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Overman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Overman more than expected).

Fields of papers citing papers by Michael J. Overman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Overman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Overman. The network helps show where Michael J. Overman may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael J. Overman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael J. Overman Line = papers co-authored together Michael J. Overman links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 454 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Hit paper breakdown →
20172014
2
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Hit paper breakdown →
20181455
3
Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
Hit paper breakdown →
20091014
4
Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases
Hit paper breakdown →
2008431
5 2009378
6
Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018
Hit paper breakdown →
2019378
7 2011275
8 1995263
9 2019258
10 2012249
11 2011243
12
Clinical and molecular characterization of early‐onset colorectal cancer
Hit paper breakdown →
2019242
13 2017204
14 2014203
15 2014194
16 2015188
17 2010179
18 2010175
19 2009175
20
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
Hit paper breakdown →
2022167

About Michael J. Overman

Michael J. Overman is a scholar working on Oncology, Pathology and Forensic Medicine, Cancer Research, Pulmonary and Respiratory Medicine and Surgery, having authored 454 papers that have together received 16.9k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (154 papers), Genetic factors in colorectal cancer (99 papers), Cancer Genomics and Diagnostics (87 papers), Cancer Immunotherapy and Biomarkers (66 papers), Pancreatic and Hepatic Oncology Research (47 papers), Intraperitoneal and Appendiceal Malignancies (35 papers), Gastric Cancer Management and Outcomes (34 papers) and Gastrointestinal Tumor Research and Treatment (33 papers). The work is most often cited by research in Oncology (8.9k citations), Hepatology (1.8k citations), Pathology and Forensic Medicine (3.1k citations), Gastroenterology (918 citations) and Cancer Research (2.4k citations). Michael J. Overman has collaborated with scholars based in United States, Italy and France. Frequent co-authors include Scott Kopetz, Cathy Eng, Robert A. Wolff, Sara Lonardi, Thierry André, Heinz‐Josef Lenz, Andrew Hill, Rebecca A. Moss, Jean-Marie Ledeine and Jean‐Nicolas Vauthey. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Oncologist, Clinical Cancer Research and Clinical Colorectal Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact